Skip to main content
. 2021 Feb 15;16:86. doi: 10.1186/s13023-020-01658-4

Fig. 3.

Fig. 3

Percentages of patients using C1-INH(SC) who demonstrated minimal clinically important difference (MCID) improvements from baseline to end-of-study. C1-INH(SC) subcutaneous C1-inhibitor, EQ-5D European Quality of Life-5 Dimensions Questionnaire, HADS Hospital Anxiety and Depression Scale, TSQM Treatment Satisfaction Questionnaire for Medication, WPAI Work Productivity and Activity Impairment Questionnaire